Risperdal Articles

Healthy full-year results for many US pharmaceutical companies

27 January 2000

US pharmaceutical majors show strong sales growth for third quarter

20 October 1999

J&J buys Centocor in $4.9 billion stock swap, profits up 15%

22 July 1999

US doctors to justify costly antipsychotics

2 June 1999

Risperidone tops haloperidol in reducing schizophrenia relapse

18 May 1999

Strong 1st quarters from US drug majors still disappoint some analysts

21 April 1999

Future growth of the global pharmaceutical market evaluated by MSDW

23 February 1999

Major US pharma companies post strong rise in sales for full year 1998

27 January 1999

Risperdal Outperforms Zyprexa In US Study

6 November 1998

Latest Wave Of US 1st Quarter Results

29 October 1998

US Majors Post Strong Earnings For 3rd Quarter

15 October 1998

Scios To Copromote SmithKline Beecham's Paxil

17 September 1998

Healthy Second-Quarter Growth For US Drug Firms

29 July 1998

US Psychiatric Drug "Price-Gouging:" Report

17 July 1998

High Hopes For HMR's Novel Antipsychotic

15 July 1998

FDA Says Pfizer's Zeldox Is "Non-Approvable"

24 June 1998

Risperdal "More Cost Effective" Than Zyprexa

15 June 1998

Zyprexa Lowers Risk Of Hyperprolactinemia

15 June 1998

SB Refocuses Memric Development

23 April 1998

Metrifonate Shows Efficacy In Behavior Dysfunction

11 March 1998

Strong Growth For US Drug Firms In 1997

28 January 1998

Israel OKs Extra Funding For New Drug Therapies

12 January 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

Janssen-Cilag Launches Once-Daily Risperdal

6 November 1997

Lundbeck Looks To Continue Strong Growth

6 November 1997

J&J 3rd Qtr Earnings Rise But Sales Hit By Strong $

16 October 1997

Mental Health Study Slams Managed Care

24 September 1997

Seroquel To Debut In First Market, The UK

18 September 1997

Risperidone Use For The Signs Of Dementia

27 August 1997

Zeneca's Seroquel Gains UK Approval, Its First

5 August 1997

Solid Growth For US Firms Despite Strong $

24 July 1997

Zeneca's Seroquel Nears Market Approval

16 July 1997

Janssen Contests Lilly's Risperdal/Zyprexa Study

3 July 1997

Synthelabo's Amisulpride Nears UK Approval

26 June 1997

Lilly's Zyprexa "More Effective" Than Risperdal; Company Highlights Drug

19 June 1997

Strong $ Impact On 1st Qtr At Johnson & Johnson

22 April 1997

Bid To Change California Mental Illness Drug Policy

9 April 1997

Janssen Accrues 1 Mill Risperdal Patient Years

25 March 1997

Lilly Shares Drop On Bad Zyprexa News

10 March 1997

US Rx Drug Sales For 1996 Up 10% At $85.35 Billion

24 February 1997

Israel: Updating The Drug Basket, Funding Innovation

10 February 1997

Significant Increases For US Drug Firms In 1996

3 February 1997

Continued Approval Of Blockbuster Products In '97?

23 December 1996

Product News In 1996 Dominated By CNS

23 December 1996

Janssen Pharmaceutica's Risperdal "Is Effective" - Six Years On

16 December 1996

Janssen-Cilag To Initiate Clinical Trial In First-Episode

25 November 1996

Major US Drug Cos Post Strong Results In 3rd Qtr

28 October 1996

Lilly Launches Zyprexa In Its First Markets

21 October 1996

Zyprexa Gains 1st Approvals In USA/EU For Schizophrenia

7 October 1996

Janssen Pharma's Futurum For Schizophrenia

9 September 1996

Zeneca Files First European Seroquel Dossier

19 August 1996

Janssen Receives Approval For Oral Risperdal

29 July 1996

US Drug Majors See 2nd-Half Double-Digit Growth

29 July 1996

FDA Panel Backs Sertindole, But Safety Issues Raised

22 July 1996

First Market Launch of Serdolect

15 July 1996

First Appro Of Sertindole In UK; Launch Imminent

1 July 1996

US Firms' Strong 1st Qtr Lifts Share Prices

29 April 1996

Atypical Antipsychotic Cuts Schizophrenia Costs

8 April 1996

Risperdal Launched In France

1 April 1996

Transition For AHP in 1995; Year-End Results

5 February 1996

Prix Galien For Roche And Glaxo Wellcome

29 January 1996

Phase III Data With Lilly's Olanzapine

8 January 1996

Zeneca Reveals Typically Strong Pipeline

18 December 1995

US Drug Cos Reveal Strong Growth In 1995 3rd Qtr

30 October 1995

Lilly Submits Olanzapine For Approval Worldwide

2 October 1995

Beleaguered Dutch Pharma Market Manages 5% Growth

21 August 1995

European Markets For Neuroleptic drugs

7 August 1995

Strong International Sales For US Cos In 2nd Qtr

31 July 1995

US Sales of Generic Drugs Up 29% In 1994, Says IMS

17 July 1995

Weaker US Dollar And Volume Growth Lift 1st Qtr

24 April 1995

End Of Year Encouraging For US Companies

6 February 1995

Risperidone For Tourette's

12 December 1994

Pfizer's Fruitful Product Pipeline

7 November 1994

Solid 3rd Qtr Growth For Large Pharma Cos

31 October 1994

Risperdal Sales In USA

17 October 1994

Strong Gains By US Firms In 2nd Quarter

1 August 1994

Phase II Results With Lilly's Olanzapine

18 July 1994

ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES

31 January 1994

FDA YEAR-END APPROVALS FOR 1993

10 January 1994

STUDY SAYS CLOZARIL USE SAVES MONEY

15 November 1993

RISPERDAL LAUNCHED IN UK

31 May 1993

SB AND J&J TO COPROMOTE IN USA

24 May 1993

RECOMMENDATION FOR RISPERDAL APPROVAL

17 May 1993

SCHIZOPHRENIA MARKET WORTH $2 BILLION BY 2002

17 May 1993

NEUROPHARMACEUTICAL MARKET IN USA

19 April 1993

FOCUS ON JANSSEN'S RISPERDOL

16 March 1992

Teva's generic Risperdal cleared in USA